# Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC

> **NCT05718882** · NA · TERMINATED · sponsor: **RenJi Hospital** · enrollment: 5 (actual)

## Conditions studied

- Liver Cancer
- Hepatocellular Carcinoma
- Resistant Cancer

## Interventions

- **DRUG:** Lenvatinib Oral Product Plus VIC1911

## Key facts

- **NCT ID:** NCT05718882
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-30
- **Primary completion:** 2024-04-02
- **Final completion:** 2024-04-02
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was terminated because the originally planned VIC-1911 dose-escalation scheme (100 mg, 150 mg, 200 mg BID) was scientifically unjustified, lacking prior clinical safety data to support such starting doses when combined with lenvatinib in HC
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05718882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05718882, "Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05718882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*